CMO companies that have been manufacturing cephalosporin antibiotics upon consignment are either shutting down or reducing their business one after another. Given the limited number of domestic manufacturers, existing consignors are in a rush to find new consignees.

Due to this, industry concerns are rising over how this breakaway among consignees may accelerate due to the increased production cost and lead to an antibiotic crisis in the second half of the year.

◆3 CMOs discontinue or reduce manufacture in 6 months

According to industry sources on the 3rd, A mid-sized pharmaceutical company, Company A, recently delivered its plan to discontinue the manufacture of ce